

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of the claims in this application.

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A CD28 peptide mimetic for blocking deleterious T cell mediated immune reaction,

said peptide mimetic being 20 to 25 amino acids in length,

said peptide mimetic comprising levorotary or dextrorotary amino acids,

wherein the peptide mimetic comprises the sequence set forth in SEQ. ID NO: 5 when the peptide mimetic comprises levorotary amino acids; and

wherein the peptide mimetic comprises the sequence set forth in SEQ ID NO: 6 when the peptide mimetic comprises dextrorotary amino acids.

2. (Cancelled)

3. (Original) The peptide mimetic of claim 1 wherein the amino and carboxyl ends of the peptide are end blocked.

4. (Presently Amended) The peptide mimetic of claim 1, wherein the binding affinity of the peptide mimetic for the B7₁ protein is from 10 fold greater to 2 fold less than the binding affinity of CD 28 for the B7₁ protein.

5. (Presently Amended) The peptide mimetic of claim 1, wherein the binding affinity of the peptide mimetic for the B7₁ protein is less than the binding affinity of CTLA-4 for the B7₁ protein.

6. (Presently Amended) The peptide mimetic of claim 1, wherein the K_d of the mimetic with respect to B7₁ is from 2 to 3 micromoles.

7-9 (Cancelled)

10. (Previously Presented) A CD28 peptide mimetic for blocking deleterious T cell mediated immune reaction, wherein said peptide mimetic is 20 or 21 amino acids in length and comprises levorotary or dextrorotary amino acids, and wherein the peptide mimetic comprises the sequence set forth in SEQ ID NO: 5 when the peptide mimetic comprises levorotary amino acids or the amino acid sequence set forth in SEQ ID NO: 6 when the peptide mimetic comprises dextrorotary amino acids.

11-12 (Cancelled)

13. (Previously Presented) The peptide mimetic of claim 10, wherein said peptide mimetic is 20 amino acids in length, and wherein the sequence of said peptide mimetic is SEQ ID NO: 5 or SEQ ID NO: 6.

14-16 (Cancelled)

17. (Withdrawn) A method of treating a subject with a T cell mediated disorder or autoimmune disease comprising: administering a biologically effective amount of one or more CD 28 peptide mimetics of claim 1 to said subject.

18. (Withdrawn) The method of claim 17, wherein the subject has multiple sclerosis.

19. (Cancelled)

20. (Withdrawn) The method of claim 17, wherein the amino and carboxyl ends of the one or more peptide mimetics are end blocked.

21-25 (Cancelled)

26. (Withdrawn) The method of claim 17, wherein said peptide mimetic is 20 amino acids in length and has the sequence set forth in SEQ ID NO: 5 or SEQ ID NO: 6.

Application No. 09/990,574
Attorney Docket No. 18525/04028
Response to Office Action

27. (Withdrawn) The method of claim 17, wherein said peptide mimetic is 20 amino acids in length and has the sequence set forth in SEQ ID NO: 5 or SEQ ID NO: 6 and wherein the subject has multiple sclerosis.

28-32 (Cancelled)